In chronic phase, this response failure can be explained in about 25% of cases by the growth of CML cells that exhibit point mutations in the BCR-ABL kinase domain [2], [3]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.